{"id":110456,"date":"2025-09-30T16:16:01","date_gmt":"2025-09-30T16:16:01","guid":{"rendered":"https:\/\/insights.greyb.com\/?post_type=ht_kb&p=110456"},"modified":"2025-09-30T16:16:04","modified_gmt":"2025-09-30T16:16:04","slug":"regeneron-patents","status":"publish","type":"ht_kb","link":"https:\/\/insights.greyb.com\/regeneron-patents\/","title":{"rendered":"Regeneron Patents – Insights & Stats (Updated 2025)"},"content":{"rendered":"\n

Regeneron has a total of 23419 patents globally, out of which 8198 have been granted. Of these 23419 patents, more than 91% patents are active. United States of America is where Regeneron has filed the maximum number of patents, followed by Japan and Israel. Parallelly, USA seems to be the main focused R&D centre and also is the origin country of Regeneron.<\/p>\n\n\n\n

Regeneron Pharmaceuticals founded in 1988, is a biotechnology company dedicated to inventing, developing, and commercializing life-transforming medicines for serious diseases. With a growing global network, the company is redefining approaches to science, manufacturing, and commercialization, while shaping new ways to think about health and innovation.<\/p>\n\n\n\n

Do read about some of the most popular patents of Regeneron which have been covered by us in this article and also you can find Regeneron patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Regeneron patent portfolio.<\/p>\n\n\n\n

How many patents does Regeneron have?<\/strong><\/h3>\n\n\n\n

Regeneron has a total of 23419 patents globally. These patents belong to 8443 unique patent families. Out of 23419 patents, 21287 patents are active.<\/p>\n\n\n\n

How Many Patents did Regeneron File Every Year?<\/strong><\/h3>\n\n\n\n
\"Regeneron<\/a><\/figure>\n\n\n\n

Are you wondering why there is a drop in patent filing for the last two years? <\/strong>It is because a patent application can take up to 18 months to get published. Certainly, it doesn\u2019t suggest a decrease in the patent filing.<\/p>\n\n\n\n

Year of Patents Filing or Grant<\/strong><\/td>Regeneron Pharmaceuticals Applications Filed<\/strong><\/td>Regeneron Pharmaceuticals Patents Granted<\/strong><\/td><\/tr>
2025<\/td>396<\/td>936<\/td><\/tr>
2024<\/td>1378<\/td>1313<\/td><\/tr>
2023<\/td>1931<\/td>1174<\/td><\/tr>
2022<\/td>2337<\/td>895<\/td><\/tr>
2021<\/td>2121<\/td>905<\/td><\/tr>
2020<\/td>2492<\/td>801<\/td><\/tr>
2019<\/td>2119<\/td>700<\/td><\/tr>
2018<\/td>1841<\/td>567<\/td><\/tr>
2017<\/td>1627<\/td>400<\/td><\/tr>
2016<\/td>1300<\/td>271<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How many Regeneron patents are Alive\/Dead?<\/strong><\/h3>\n\n\n\n

Worldwide Patents<\/strong><\/p>\n\n\n\n

\"Regeneron<\/a><\/figure>\n\n\n\n

How Many Patents did Regeneron File in Different Countries?<\/strong><\/h3>\n\n\n\n
\"Worldwide<\/a><\/figure>\n\n\n\n

Countries in which <\/strong>Regeneron Filed Patents<\/strong><\/strong><\/h3>\n\n\n\n
Country<\/strong><\/td>Patents<\/strong><\/td><\/tr>
United States of America<\/td>2277<\/td><\/tr>
Japan<\/td>1540<\/td><\/tr>
Israel<\/td>1432<\/td><\/tr>
Europe (EPO)<\/td>1215<\/td><\/tr>
Mexico<\/td>1165<\/td><\/tr>
Hong Kong (S.A.R.)<\/td>1138<\/td><\/tr>
Australia<\/td>1132<\/td><\/tr>
Korea (South)<\/td>1107<\/td><\/tr>
China<\/td>1077<\/td><\/tr>
Singapore<\/td>1018<\/td><\/tr>
South Africa<\/td>1017<\/td><\/tr>
Canada<\/td>766<\/td><\/tr>
Brazil<\/td>618<\/td><\/tr>
Eurasia<\/td>556<\/td><\/tr>
India<\/td>533<\/td><\/tr>
Taiwan<\/td>455<\/td><\/tr>
Malaysia<\/td>414<\/td><\/tr>
Russia<\/td>366<\/td><\/tr>
Spain<\/td>337<\/td><\/tr>
Indonesia<\/td>276<\/td><\/tr>
Hungary<\/td>255<\/td><\/tr>
Denmark<\/td>245<\/td><\/tr>
Poland<\/td>227<\/td><\/tr>
Morocco<\/td>225<\/td><\/tr>
Portugal<\/td>218<\/td><\/tr>
New Zealand<\/td>212<\/td><\/tr>
Philippines<\/td>196<\/td><\/tr>
Argentina<\/td>179<\/td><\/tr>
Republic Of Moldova<\/td>166<\/td><\/tr>
Slovenia<\/td>163<\/td><\/tr>
Lithuania<\/td>158<\/td><\/tr>
Croatia<\/td>155<\/td><\/tr>
Colombia<\/td>154<\/td><\/tr>
Serbia<\/td>153<\/td><\/tr>
Turkey<\/td>152<\/td><\/tr>
Bulgaria<\/td>142<\/td><\/tr>
Thailand<\/td>140<\/td><\/tr>
Viet Nam<\/td>138<\/td><\/tr>
Tunisia<\/td>122<\/td><\/tr>
Chile<\/td>88<\/td><\/tr>
Romania<\/td>70<\/td><\/tr>
Latvia<\/td>63<\/td><\/tr>
Finland<\/td>62<\/td><\/tr>
Ireland<\/td>54<\/td><\/tr>
Macao<\/td>53<\/td><\/tr>
Saudi Arabia<\/td>32<\/td><\/tr>
Norway<\/td>19<\/td><\/tr>
Ukraine<\/td>18<\/td><\/tr>
Gulf Cooperation Council<\/td>17<\/td><\/tr>
Germany<\/td>16<\/td><\/tr>
United Kingdom<\/td>11<\/td><\/tr>
Uruguay<\/td>11<\/td><\/tr>
Africa<\/td>10<\/td><\/tr>
Austria<\/td>9<\/td><\/tr>
Costa Rica<\/td>9<\/td><\/tr>
Netherlands<\/td>8<\/td><\/tr>
Luxembourg<\/td>6<\/td><\/tr>
Italy<\/td>6<\/td><\/tr>
France<\/td>3<\/td><\/tr>
Belgium<\/td>2<\/td><\/tr>
Czech Republic<\/td>1<\/td><\/tr>
Malta<\/td>1<\/td><\/tr>
Albania<\/td>1<\/td><\/tr>
Cyprus<\/td>1<\/td><\/tr>
Estonia<\/td>1<\/td><\/tr>
North Macedonia<\/td>1<\/td><\/tr>
Slovakia<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

10 Best Regeneron Patents<\/strong><\/strong><\/h3>\n\n\n\n

WO2015112800A1<\/a> is the most popular patent in the Regeneron portfolio. It has received 879 citations so far from companies like Asia Biotech Pte Ltd, Novartis and Anaptysbio.<\/strong><\/p>\n\n\n\n

Below is the list of 10 most cited patents of Regeneron:<\/strong><\/p>\n\n\n\n

Publication Number<\/strong><\/td>Citation Count<\/strong><\/td><\/tr>
WO2015112800A1<\/a><\/td>879<\/td><\/tr>
WO2015088643A1<\/a><\/td>241<\/td><\/tr>
US10787501B1<\/a><\/td>221<\/td><\/tr>
US8945559B2<\/a><\/td>189<\/td><\/tr>
US9987500B2<\/a><\/td>182<\/td><\/tr>
US9657102B2<\/a><\/td>169<\/td><\/tr>
WO2017062888A1<\/a><\/td>165<\/td><\/tr>
US9018356B2<\/a><\/td>141<\/td><\/tr>
WO2015143079A1<\/a><\/td>140<\/td><\/tr>
US20170174779A1<\/a><\/td>138<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What Percentage of <\/strong>Regeneron <\/strong>US Patent Applications were<\/strong> <\/strong>Granted?<\/strong><\/strong><\/h3>\n\n\n\n

Regeneron (Excluding its subsidiaries) has filed 2337 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1150 have been granted leading to a grant rate of 77.03%.<\/strong><\/p>\n\n\n\n

Below are the key stats of Regeneron patent prosecution at the USPTO.<\/strong><\/p>\n\n\n\n

\"EA<\/a><\/figure>\n\n\n\n

Which Law Firms are managing US Patents for Regeneron?<\/strong><\/h3>\n\n\n\n
Law Firm<\/strong><\/td>Total Applications<\/strong><\/td>Success Rate<\/strong><\/td><\/tr>
Fisherbroyles Llp<\/td>214<\/td>72.42%<\/td><\/tr>
Schwabe W&W Pc<\/td>199<\/td>88.32%<\/td><\/tr>
Alston & Bird Llp<\/td>168<\/td>73.81%<\/td><\/tr>
Kramer Levin Naftalis & Frankel Llp<\/td>160<\/td>95.95%<\/td><\/tr>
Scully Scott Murphy & Presser Pc<\/td>155<\/td>89.34%<\/td><\/tr>
Regeneron Pharmaceuticals (Inhouse IP Dept.)<\/td>153<\/td>65.32%<\/td><\/tr>
Mccarter & English Llp<\/td>140<\/td>54.70%<\/td><\/tr>
Armstrong Teasdale<\/td>130<\/td>86.67%<\/td><\/tr>
Merchant & Gould<\/td>101<\/td>61.97%<\/td><\/tr>
Bookoff Mcandrews<\/td>99<\/td>82.93%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What are Regeneron key innovation segments?<\/strong><\/h3>\n\n\n\n\n